C12N 2795/10232
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2795/10232 (Use of virus as therapeutic agent, other than vaccine) appears on 39 US grants and 64 published applications in this corpus.
Search patents in C12N- Granted patents
- 39
- Published applications
- 64
- Assignees
- 46
- Inventors
- 141
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 2 |
| 2011 | 2 | 2 |
| 2012 | 3 | 3 |
| 2013 | 1 | 0 |
| 2014 | 0 | 3 |
| 2015 | 0 | 2 |
| 2016 | 1 | 2 |
| 2017 | 1 | 3 |
| 2018 | 2 | 2 |
| 2019 | 2 | 8 |
| 2020 | 3 | 3 |
| 2021 | 6 | 6 |
| 2022 | 3 | 2 |
| 2023 | 4 | 2 |
| 2024 | 3 | 9 |
| 2025 | 4 | 3 |
| 2026 | 3 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bacteriophage, bacterial wilt disease control agent, and bacterial wilt disease control method14 Apr 2026US 12,599,142 B2Panefri Industrial Co., Ltd.
- Bacteriophage compositions for treating Pseudomonas infection7 Apr 2026US 12,594,312 B2Armata Pharmaceuticals, Inc.
- Bacteriophage compositions and methods for treatment of bacterial infections17 Mar 2026US 12,576,119 B2Baylor College of Medicine
- Bacteriophage for modulating inflammatory bowel disease19 Aug 2025US 12,390,499 B2Biomx Ltd.
- Bacteriophage compositions24 Jun 2025US 12,337,020 B2Takeda Pharmaceutical Company Limited
- Bacteriophages and use thereof for the treatment or prevention of infection caused by salmonella gallinarum23 Jul 2026US 2026/0207687 A1Purdue Research Foundation
- Disposable personal care products composed of nonwoven fabrics coated with bacteriophages to prevent and reduce bacterially caused skin problems9 Jul 2026US 2026/0191922 A1Parallel Health, Inc.
- Staphylococcus phage compositions and cocktails thereof7 May 2026US 2026/0124259 A1Locus Biosciences, Inc.
- Bacteriophage compositions and methods for treatment of bacterial infections23 Apr 2026US 2026/0108570 A1The University of Chicago
- Simultaneous production of structural proteins from heterologous bacteriophage in cell-free expression system2 Apr 2026US 2026/0092261 A1Technische Universität München
Most cited
By later US patents
- Phage therapy against Pseudomonas aeruginosa30US 8,282,920 B2Industry-University Cooperation Foundation Sogang University · 2012
- Engineered enzymatically active bacteriophage and methods for dispersing biofilms20US 8,153,119 B2Massachusetts Institute of Technology · 2012
- Method for bacteriophage delivery and amplification7US 7,951,579 B2Board of Trutees of the University of Arkansas · 2011
- Phage therapy of pseudomonas infections6US 10,077,431 B2Pherecydes Pharma · 2018
- Phage therapy of Pseudomonas infections3US 10,260,051 B2Pherecydes Pharma · 2019